<figure><img src="https://reader.miniflux.app/proxy/CJTaLB4c9ntj3DEcxNSovvYG71si5rTn3i8bUdwJZvI=/aHR0cHM6Ly9hYnNvbHV0ZWx5bWF5YmUucGxvcy5vcmcvd3AtY29udGVudC91cGxvYWRzL3NpdGVzLzgvMjAyMy8wNy9FbWVyZ2VuY3ktdmF4LTkxOHgxMDI0LmpwZw==" alt="There&#39;s an enthusiastic cartoon vaccine vial in a glass case on a wall. Above it is a sign saying &#34;In case of emergency&#34;. (Cartoon by Hilda Bastian.)" width="270" height="301" srcset="https://reader.miniflux.app/proxy/CJTaLB4c9ntj3DEcxNSovvYG71si5rTn3i8bUdwJZvI=/aHR0cHM6Ly9hYnNvbHV0ZWx5bWF5YmUucGxvcy5vcmcvd3AtY29udGVudC91cGxvYWRzL3NpdGVzLzgvMjAyMy8wNy9FbWVyZ2VuY3ktdmF4LTkxOHgxMDI0LmpwZw== 918w, https://reader.miniflux.app/proxy/F3m549vt3toJZ6FaAYVq30RGpUdzggTrLEGpsWW9Fc4=/aHR0cHM6Ly9hYnNvbHV0ZWx5bWF5YmUucGxvcy5vcmcvd3AtY29udGVudC91cGxvYWRzL3NpdGVzLzgvMjAyMy8wNy9FbWVyZ2VuY3ktdmF4LTI2OXgzMDAuanBn 269w, https://reader.miniflux.app/proxy/idtWaJwpN8kgh0ir7io18BMVjTpkgglGgQaoEht-9A0=/aHR0cHM6Ly9hYnNvbHV0ZWx5bWF5YmUucGxvcy5vcmcvd3AtY29udGVudC91cGxvYWRzL3NpdGVzLzgvMjAyMy8wNy9FbWVyZ2VuY3ktdmF4LTc2OHg4NTcuanBn 768w, https://reader.miniflux.app/proxy/DeHZpmYeTaQvdd5Msw_zCuP_h4-CAmELL_uQRmsAKW8=/aHR0cHM6Ly9hYnNvbHV0ZWx5bWF5YmUucGxvcy5vcmcvd3AtY29udGVudC91cGxvYWRzL3NpdGVzLzgvMjAyMy8wNy9FbWVyZ2VuY3ktdmF4LTEzNzd4MTUzNi5qcGc= 1377w, https://reader.miniflux.app/proxy/TKIjv0bqyGOlkPRwOQoa6g6Rfb6JfMZb11I8zANYO1s=/aHR0cHM6Ly9hYnNvbHV0ZWx5bWF5YmUucGxvcy5vcmcvd3AtY29udGVudC91cGxvYWRzL3NpdGVzLzgvMjAyMy8wNy9FbWVyZ2VuY3ktdmF4LTE4MzV4MjA0OC5qcGc= 1835w" sizes="(max-width: 270px) 100vw, 270px" loading="lazy"/></figure>







<p>This update is packed with news, with 3 developments standing out in particular. The first is the “major hat” in this post’s title. It’s a new consortium of major scientific groups, along with a major global pharmaceutical company, spanning bases in Israel, the US, and Europe. That’s everything that’s needed for the very heavy – and expensive – lift of running late-stage clinical trials, large-scale manufacturing, and working with regulators that’s needed to get a vaccine on the market. They don’t have a vaccine yet, but the goal is one that can protect not just against Covid-19 and its next variants, but other coronaviruses as well.</p>



<p>Another of the trio of developments is related to pancoronavirus vaccine. An American group that’s been working on this since 2021 have reported preclinical results of a “cocktail” approach that resulted in hamsters being protected against not just recent Omicron strains, but 2 bat coronaviruses as well. They sound optimistic about being able to use this approach to develop a broadly protective next-generation vaccine.</p>



<p>The third is further along. It’s an intranasal booster vaccine, that’s showing signs of providing mucosal immunity in a phase 1 trial – and the university has formed a company to help develop it.</p>



<p>Those highlights and more below, broken down into 3 categories of next-generation Covid vaccines (<a href="#definitions">definitions below</a>).</p>







<p> </p>



<h2 id="contents"></h2>







<ul><li><a href="#mucosal">Mucosal</a> vaccine news</li><li>Covid-19 <a href="#panSARS2">“variant-proof”</a> vaccine news</li><li><a href="#pancoronavirus">Pancoronavirus</a> vaccine news</li><li><em>Addendum 1:</em> Table of <a href="#mucosaltable">mucosal vaccines</a> in clinical trials</li><li><em>Addendum 2: </em>Table of <a href="#pantable">pancoronavirus vaccines</a> with results</li><li><em>Addendum 3:</em> <a href="#definitions">Definitions</a> of vaccine types</li></ul>



<h2 id="mucosal"></h2>







<h4>Mucosal vaccine news</h4>







<p>We’ll start with one of the big bits of news I mentioned in the introduction. It’s about the NDV-HXP-S vaccine, developed in the US at Mount Sinai in New York. The vaccine is available for development without royalties in lower income countries, and 4 have developed versions: Brazil, Mexico, Thailand, and Vietnam. Both the original developers, and the team at Avi-Mex in Mexico (where the vaccine is called Patria), have been testing intranasal versions.</p>



<p>This vaccine is a viral vector vaccine, using the Newcastle Disease Virus (either live or inactivated). It couples the ability for old school manufacture – in eggs, like flu vaccine – with Hexapro, a major advance in the way the Covid protein is modified, hoping to be more potent than first-generation vaccines. (Carl Zimmer wrote a great article about this <a href="https://www.nytimes.com/2021/04/05/health/hexapro-mclellan-vaccine.html" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">in 2021</a>.)</p>



<p>There are 3 bits of news on this vaccine:</p>



<ul><li>Mount Sinai have <a href="https://www.mountsinai.org/about/newsroom/2022/mount-sinai-announces-the-formation-of-castlevax-inc-a-clinical-stage-infectious-diseases-company-developing-novel-vaccines-and-therapeutics-targeting-pandemic-threats-and-diseases-of-unmet-medical-need" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">formed a company</a>, called <a href="https://www.castlevax.com/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">CastleVax</a>, to raise funds and develop the vaccine further;</li><li>A <a href="https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4503317" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">report of preclinical results</a> for the intranasal vaccine in mice was released; and</li><li>In <a href="https://www.mountsinai.org/about/newsroom/2023/promising-results-of-next-generation-intranasal-covid-booster-vaccine-implications-for-infection-prevention-and-transmission" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">a press release</a>, Mount Sinai said that preliminary analysis of a phase 1 trial in the US showed particularly positive results for the intranasal version.</li></ul>



<p>There’s no data provided on those clinical trial results. According to the <a href="https://clinicaltrials.gov/study/NCT05181709" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">registered report</a> for this trial, it’s a small trial (35 participants). The press release says that an intranasal booster resulted in saliva levels showing signs of mucosal immunity, as well as systemic immunity. Better mucosal immunity could help reduce infection and transmission of Covid-19. (Results from a phase 1 trial in Mexico that included intranasal boosting <a href="https://www.nature.com/articles/s41541-023-00662-6" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">have been published</a>.)</p>



<p>A couple of reports of preclinical results stood out in the last month, too. The first is <a href="https://www.biorxiv.org/content/10.1101/2023.07.14.549076v1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">a report</a> for a vaccine against both Covid and Influenza A from the University of Manitoba. The developers tested their viral vector vaccine in oral and intranasal forms, and concluded results were somewhat similar. (There were only challenge studies for influenza, not Covid.)</p>



<p>Finally, there were <a href="https://www.sciencedirect.com/science/article/pii/S0264410X23007831" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">preclinical results comparing</a> an intranasal vaccine with Moderna Covid vaccine. The intranasal vaccine (VLP-RBD-BECC) was developed by West Virginia University (USA), and the results were previously available in a preprint. Both protected mice from challenge with the Delta variant, however the developers found less lung inflammation early on for those administered the intranasal vaccine.</p>







<p><em><a href="#contents">Back to contents</a></em></p>



<h2 id="panSARS2"></h2>







<h4>Covid-19 “variant-proof” vaccine news</h4>







<p>This category is complicated, because it’s hard to define it properly. There were clinical trial results this month for a vaccine that I think fits at least roughly into the category of trying to provide broad SARS-CoV-2 protection. It’s a tetravalent version of Sinocelltech’s protein subunit vaccine (China).</p>



<p><a href="https://www.nature.com/articles/s41467-023-39766-x" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">This report</a> includes preliminary safety and immunogenicity results for a subset of 449 men (and 1 woman) from a small <a href="https://classic.clinicaltrials.gov/ct2/show/NCT05323461" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">ongoing phase 3 trial</a>. (There is also a <a href="https://clinicaltrials.gov/study/NCT05308576" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">10,000-participant phase trial</a> underway in China for this tetravalent vaccine.)</p>



<p>The tetravalent vaccine, SCTV01E, targets Alpha, Beta, Delta and Omicron BA.1 variants (in a ratio of 1:1:1:3). It was tested as a booster in people who have either had Covid or been vaccinated, and it’s compared to the original version of the BNT/Pfizer vaccine (not a recent one adapted for variants), and SCTV01C – a bivalent version of Sinocelltech’s vaccine (targeting Alpha and Beta), and in a lower dose than the SCTV01E.</p>



<p>The rate of adverse effects for the tetravalent vaccine were lower than for the BNT/Pfizer vaccine, and signs of immune response were stronger, including for BA.5, an Omicron variant that emerged after this vaccine was developed. It’s too soon to know if this equates to better protection, and how that might compare with other Omicron-adapted vaccines.</p>







<p><em><a href="#contents">Back to contents</a></em></p>



<h2 id="pancoronavirus"></h2>







<h4>Pancoronavirus vaccine news</h4>







<p>I mentioned a pair of big developments in this category in the introduction – a new collaboration, and some particularly noteworthy preclinical results from another group.</p>



<p><a href="https://sheba-global.com/spri-unveils-vaccine-agenda-to-combat-corona-variants-new-pandemic/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">The new collaboration</a> is between the Sheba Pandemic Research Institute (SPRI) in Israel –  itself a new collaboration between Sheba Medical Center in Israel and the NIH’s <a href="https://www.niaid.nih.gov/about/vrc" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Vaccine Research Center</a> in the US – and the US Walter Reed Army Institute of Research (WRAIR), as well as Sanofi (a global pharmaceutical manufacturer, based in Europe).</p>



<p>WRAIR has been working on a pancoronavirus vaccine since quite early in the pandemic, and has had one in phase 1 trial. (You can catch up with the research on their 2 vaccines in <a href="#pantable">the table below</a>.) Sheba Medical Center will be contributing their massive database to the effort. They’ve been drawing and cataloging regular blood samples for their over 10,000 staff since before the arrival of SARS-CoV-2 in Israel. So it’s a massive trove of data across waves of variants that the group can analyze, looking for common features.</p>



<p>A spokesperson for the collaboration talked about the possibility of <a href="https://www.timesofisrael.com/sheba-pandemic-research-institute-and-partners-developing-pan-coronavirus-vaccine/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">having a vaccine in mid-2024</a>. That’s ambitious. That said, having a major pharmaceutical company interested in the potential vaccine makes that imaginable if it all goes very well.</p>



<p>The other big news in this category comes from the University of Wisconsin-Madison, with a team that’s been getting <a href="https://reporter.nih.gov/search/lyNeGUcA6U2NmnoaZg2riQ/projects" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">several considerable NIH grants</a> for this work since 2021. <a href="https://www.researchsquare.com/article/rs-3088907/v1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">A third report</a> of preclinical results was released from this group, still in non-primates, and this one is worth digging into in some detail.</p>



<p>This group, including people from Georgia Tech, is working on protein subunit vaccines. The developers have moved onto testing vaccines made using “cocktails” of proteins. After testing immune responses in hamsters to vaccines based on single proteins from a wide variety of coronaviruses, they chose those that stimulated the greatest immune responses to a variety of coronaviruses, as well as providing protection in challenge tests. They created a pair of cocktails – a bivalent one, and a trivalent one that had better results.</p>



<p>For the trivalent vaccine, when hamsters were infected with coronaviruses – 2 recent Omicron variants, and 2 bat coronaviruses – they didn’t get sick, and there was no detectable virus in their lungs. They also tested some hamsters vaccinated with a bivalent BNT/Pfizer vaccine, although it was only a single low dose: Those hamsters didn’t generate signs of immune response to the coronaviruses they tested, and they didn’t have enough protection in the challenge tests.</p>



<p>These results convinced the developers that the “cocktail” approach is worth pursuing. They wrote, “this study is a valuable step towards designing a pan-sarbecovirus vaccine.” (Sarbecovirus is the group of coronaviruses that caused both the original SARS and Covid-19.)</p>



<p>I’ve also added a pair of new vaccines <a href="#pantable">to the table</a> of pancoronavirus vaccine efforts with results, one each from France and USA:</p>



<ul><li>A protein subunit vaccine from Osivax in France, with <a href="https://www.frontiersin.org/articles/10.3389/fimmu.2023.1188605/full" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">results in non-primates</a>; and</li><li>Another protein subunit vaccine, from Stanford University. That group has now released results in <a href="https://www.nature.com/articles/s41467-023-37417-9" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">primates</a> as well as <a href="https://www.biorxiv.org/content/10.1101/2023.06.27.546764v2" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">non-primates</a>.  </li></ul>







<p><em><a href="#contents">Back to contents</a></em></p>



<h2 id="mucosaltable"></h2>







<h4><em>Addendum 1: </em>Table of mucosal vaccines in clinical trials</h4>







<p><em>*  Indicates new entry since my previous update post.</em></p>







<p><em>Note: Where there is a link to “All records” for a vaccine, that’s in my public Zotero collection for the vaccine, and it may include non-mucosal studies for that vaccine. <em><em>Notes</em> <em>on that collection are <a href="https://absolutelymaybe.plos.org/2022/01/26/boosters-and-mixed-schedules-covid-vaccines-at-the-2-year-mark-part-1/#collection" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">here</a>.</em></em> <em>For details on how I track Covid vaccine progress to maintain that collection, see my <a href="https://absolutelymaybe.plos.org/2022/02/28/tracking-the-covid-vaccine-race-in-the-wild-first-2-years-a-process-story/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">background post</a>.</em></em></p>







<figure><table><thead><tr><th>Vaccine, type, manufacturer</th><th>Mucosal version(s)</th><th>Phase 1 to 2 clinical trials</th><th>Phase 3+ trial(s)</th><th>Phase 3+ efficacy or immunogenicity results</th></tr></thead><tbody><tr><td>ACM-001<br/><em>Protein subunit</em><br/><br/><em>ACM Biolabs (Singapore/Switzerland)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/ACM-001%20-%20ACM%20Biolabs/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Intranasal.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT05385991" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.</td><td></td><td></td></tr><tr><td>Ad5-nCoV (Convidecia Air)<br/><em>Viral vector</em> <em>(adenovirus)</em><br/><br/><em>CanSino (China)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/Ad5-nCov%20CanSino/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Inhaled through the mouth using a nebulizer.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04552366" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>. <strong><a href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00087-X/fulltext" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong>.<br/><br/><a href="https://clinicaltrials.gov/ct2/show/NCT05043259" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1/2</a>. <strong><a href="https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4000565" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong> (plus <strong><a href="https://www.medrxiv.org/content/10.1101/2022.07.26.22278072v1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">second later preprint</a></strong>).<br/><br/><a href="https://clinicaltrials.gov/ct2/show/NCT05330871" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 2</a> (aged 6-17 years).</td><td>10,420 people in China (<a href="https://clinicaltrials.gov/ct2/show/NCT05204589" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 3</a>).<br/><strong><a href="https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00350-X/fulltext" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong>.<br/><br/>1,350 people (<a href="https://clinicaltrials.gov/ct2/show/NCT05442684" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 3</a>).<br/><br/>540 people, in Malaysia (<a href="https://clinicaltrials.gov/ct2/show/NCT05517642" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 3</a>).<br/><br/>904 people in China (<a href="https://www.chictr.org.cn/hvshowproject.aspx?id=148875" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 4</a>).<br/><strong><a href="https://www.medrxiv.org/content/10.1101/2022.03.08.22271816v1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong>.<br/><br/>360 people (<a href="https://clinicaltrials.gov/ct2/show/NCT05303584" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 4</a>).</td><td>Comparison after 2-dose course of inactivated vax: Convidecia injection vs inhaled, protein subunit, or CoronaVac booster (<strong><a href="https://www.medrxiv.org/content/10.1101/2022.03.08.22271816v1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 4 results</a></strong>). Both injected &amp; inhaled Convidecia had stronger impact on signs of immunity than the others; response after inhaled version was slower but longer-lasting than injected (which peaked then declined from day 14), better for Omicron though not as good for original virus. No measure of mucosal immunity used.</td></tr><tr><td>Ad5-triCoV/Mac &amp; ChAd-triCoV/Mac<br/><em>Viral vector (adenovirus)</em><br/><br/>McMaster University/Canadian Institutes of Health Research (Canada)<br/></td><td>Aerosol.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT05094609" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/><br/></td><td></td><td></td></tr><tr><td>AdCOVID<br/><em>Viral vector</em> <em>(adenovirus)</em><br/><br/><em>AltImmune (USA)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/AdCOVID%20Altimmune/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Intranasal.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04679909" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>. <strong><a href="https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-update-adcovidtm-phase-1-clinical-trial" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong> – press release only.<br/><br/><em>Discontinued after phase 1.</em></td><td></td><td> </td></tr><tr><td>AdS+N<br/><em>Viral vector (adenovirus)</em><br/><br/><em>ImmunityBio (USA)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/AdS%2BN%20(hAd5%20S-Fusion%20%2B%20N-ETSD)%20ImmunityBio,Mucosal%20vaccine/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)<br/><br/></td><td>Intranasal, oral capsule, or sublingual.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04732468" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a> (oral).<br/><br/><a href="https://clinicaltrials.gov/ct2/show/NCT04591717" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a> (sublingual).</td><td></td><td></td></tr><tr><td>Avacc 10<br/><em>Protein subunit</em><br/><br/><em>Intravacc (Netherlands)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/Avacc%2010%20-%20Intravacc/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Intranasal.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT05604690" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.</td><td></td><td></td></tr><tr><td>bacTRL-Spike-1<br/><em>Live attenuated</em><br/><br/><em>Symvivo (Canada)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/bacTRL-Spike-1%20Symvivo/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Oral.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04334980" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.</td><td></td><td></td></tr><tr><td>BBV154 (iNCOVACC)<br/><em>Viral vector</em> <em>(adenovirus)</em><br/><br/><em>Bharat Biotech (India)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/BBV154%20Bharat/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)<br/></td><td>Intranasal.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04751682" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/><br/><a href="http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=59902" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 2</a>.<br/><br/>Small amount of data from these trials in the <a href="https://www.bharatbiotech.com/images/incovacc/incovacc-smpc.pdf" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">drug product information</a>.<br/><br/><a href="http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=59216" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 2/3</a>.<br/><br/><a href="https://clinicaltrials.gov/ct2/show/NCT05639998" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 2</a>.</td><td>In India, 2-dose course of BBV154 vs 2-dose course of injected Covaxin inactivated vaccine (<a href="http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=65443" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 3</a> – and <a href="https://clinicaltrials.gov/ct2/show/NCT05522335" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">here</a>).<br/><strong><a href="https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4342771" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong>.<br/><em>See also the <a href="https://www.bharatbiotech.com/images/incovacc/incovacc-smpc.pdf" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">drug product information</a>.</em><br/><br/>875 people in India, booster trial (<a href="http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=65451" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 3</a>).</td><td>2,998 previously unvaxed people were assigned for the intranasal iNCOVACC, 162 for injected Covaxin. This trial did not aim to assess disease outcomes. It took place during the first Omicron wave.<br/><br/>Signs of immune response were higher for iNCOVACC than Covaxin. <br/><br/>Adverse events rate very low (5% local and 3% systemic) – lower than for comparison group.</td></tr><tr><td>BV-AdCoV-1<br/><em>Viral vector (adenovirus)</em><br/><br/><em>Wuhan BravoVax</em><br/><em>(China)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/BV-AdCoV-1%20Wuhan%20BravoVax/items/NLEUGD29/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Inhaled through the mouth using a nebulizer.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT05706324" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.</td><td></td><td></td></tr><tr><td>ChAdOx1<br/><em>Viral vector (adenovirus)</em><br/><br/><em>Oxford University (UK)</em><br/><em>(This is the AstraZeneca vax)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/ChAdOx1%20nCov-19%20Oxford-AstraZeneca,Mucosal%20vaccine/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Intranasal.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04816019" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/><br/><a href="https://clinicaltrials.gov/ct2/show/NCT05007275" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/><br/><strong><a href="https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(22)00480-7/fulltext" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong>.</td><td></td><td></td></tr><tr><td>CoV2-OGEN1<br/><em>Protein subunit</em><br/><br/><em>US Specialty Formulations/VaxForm</em> <em>(USA)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/CoV2-OGEN1%20USSF%2FVaxform/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Oral.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04893512" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/>(Fully recruited, final dose in November 2022.)</td><td></td><td></td></tr><tr><td>COVI-VAC<br/><em>Live attenuated</em><br/><br/><em>Codagenix (USA, with the Serum Institute of India)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/COVI-VAC%2FCoviLiv%20Codagenix/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Intranasal.</td><td><br/><a href="https://clinicaltrials.gov/ct2/show/NCT04619628" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/><a href="https://www.prnewswire.com/news-releases/codagenix-announces-safety-and-immunogenicity-data-from-phase-1-covid-19-intranasal-vaccine-trial-and-intent-to-progress-to-phase-23-studies-301382120.html?tc=eml_cleartime" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Press release</a> stating successful (without data) and progressing to phase 2/3.<br/><strong><a href="https://europepmc.org/article/PMC/PMC8644858" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong> (conference abstract) and in <a href="https://codagenix.com/codagenix-intranasal-covid-19-vaccine-shows-potent-cellular-immune-response-against-conserved-viral-proteins-indicating-potential-for-immunogenicity-against-omicron-and-future-variants-in-phase-1-dat/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">press release</a>.<br/><br/><a href="https://clinicaltrials.gov/ct2/show/NCT05233826" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a> (booster).</td><td>Phase 2/3, as part of the <a href="https://www.isrctn.com/ISRCTN15779782" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">WHO Solidarity Trial for Vaccines</a> in <a href="https://cvd-mali.org/en/solidarity-trial-vaccines-enters-major-new-phase-recruiting-now/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Mali</a>. (<a href="https://cdn.who.int/media/docs/default-source/blue-print/who-covid-2019_solidarityvaccinetrial_14-june-2021_clean_for-registry.pdf?sfvrsn=77b2110a_11" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Protocol</a>.)</td><td></td></tr><tr><td>CVXGA1-001<br/><em>Viral vector (parainfluenza)</em><br/><br/><em>CyanVac/Blue Lake Tech (USA)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/CVXGA1-001%20-%20Uni%20of%20Georgia%2FCyanVac/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Intranasal.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04954287" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/><a href="https://clinicaltrials.gov/ct2/show/NCT05736835" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 2</a>.</td><td></td><td></td></tr><tr><td>DNS1-RBD (Pneucolin)<br/><em>Viral vector (influenza)</em><br/><br/><em>Beijing Wantai BioPharm (China)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/dNS1-RBD%20Beijing%20Wantai%20Biological%20Pharmacy%20Enterprise/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Intranasal.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04809389" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/><a href="https://clinicaltrials.gov/ct2/show/NCT05200741" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 2</a>.<br/><strong><a href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00131-X/fulltext" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Joint results</a></strong>.</td><td>30,990 participants in Colombia, Philippines, South Africa, Vietnam.<br/><strong><a href="https://www.researchsquare.com/article/rs-2407050/v1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong>.<br/><br/>5,400 participants in Ghana (<a href="https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=17163" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 3</a>).</td><td>Comparison of 2 doses of intranasal vaccine 14 days apart, with placebo control, during circulation of Omicron. Included &gt;13,000 previously unvaccinated people.<br/><br/>Efficacy shown 90 days after 2nd dose. There was some decline at 180 days.<br/><br/><em>Efficacy against symptomatic Covid:</em><br/>No previous vax: 55.2% (CI 13.8 to 76.7)<br/>Inactivated: 38.2% (CI -49.2 to 74.4)<br/>Viral vector: 39.9% (CI -16.7 to 69.1)<br/>mRNA: 10.1% (CI -45.9 to 44.5)<br/><br/><em>Efficacy against severe Covid:</em><br/>No previous vax: 66.7% (CI 8.3 to 87.9)<br/>Inactivated: 54.6% (CI -47.3 to 86.0)<br/>Viral vector: 50.0% (CI -6.8 to 76.6)<br/>mRNA: 19.5% (CI -39.2 to 53.4)<br/><br/><em>Efficacy against hospitalization:</em><br/>100% (CI -9.2 to 100)<br/><br/>Adverse events were very low – similar to placebo. Less than 8% of people had a runny and/or blocked nose or sore throat.</td></tr><tr><td>GAM-COVID-VAC (rAd26-S – Sputnik Light)<br/><em>Viral vector (adenovirus)</em><br/><br/><em>Gamaleya Research Institute (Russia)</em></td><td>Intranasal.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT05248373" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1/2</a><br/></td><td>7,000 participants in Russia (<a href="https://grls.rosminzdrav.ru/CiPermitionReg.aspx?PermYear=0&amp;DateInc=&amp;NumInc=&amp;DateBeg=&amp;DateEnd=&amp;Protocol=&amp;RegNm=&amp;Statement=&amp;ProtoId=&amp;idCIStatementCh=&amp;Qualifier=&amp;CiPhase=&amp;RangeOfApp=&amp;Torg=&amp;LFDos=&amp;Producer=%d0%9d%d0%b0%d1%86%d0%b8%d0%be%d0%bd%d0%b0%d0%bb%d1%8c%d0%bd%d1%8b%d0%b9+%d0%b8%d1%81%d1%81%d0%bb%d0%b5%d0%b4%d0%be%d0%b2%d0%b0%d1%82%d0%b5%d0%bb%d1%8c%d1%81%d0%ba%d0%b8%d0%b9+%d1%86%d0%b5%d0%bd%d1%82%d1%80+%d1%8d%d0%bf%d0%b8%d0%b4%d0%b5%d0%bc%d0%b8%d0%be%d0%bb%d0%be%d0%b3%d0%b8%d0%b8+%d0%b8+%d0%bc%d0%b8%d0%ba%d1%80%d0%be%d0%b1%d0%b8%d0%be%d0%bb%d0%be%d0%b3%d0%b8%d0%b8&amp;Recearcher=&amp;sponsorCountry=&amp;MedBaseCount=&amp;CiType=&amp;PatientCount=&amp;OrgDocOut=2&amp;Status=1%2c2%2c3%2c4%2c&amp;NotInReg=0&amp;All=0&amp;PageSize=8&amp;order=numperm&amp;orderType=desc&amp;pagenum=1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 3</a> or phase 2/3 – not clear).</td><td></td></tr><tr><td>Mambisa<br/><em>Protein subunit</em><br/><br/><em>Centre for Genetic Engineering &amp; Biotechnology </em>(<em>CIGB) (Cuba)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/Mambisa%20CIBG%2FBioCubaFarma/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Intranasal drops.</td><td><a href="https://rpcec.sld.cu/en/trials/RPCEC00000345-En" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1/2</a>.<br/><br/><a href="https://rpcec.sld.cu/en/trials/RPCEC00000382-En" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1/2</a>.<br/><strong><a href="https://www.prensa-latina.cu/2022/04/27/candidato-vacunal-mambisa-de-cuba-cumple-expectativas-de-estudios" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong> (report of a conference presentation).<br/><br/><a href="https://rpcec.sld.cu/en/trials/RPCEC00000398-En" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 2</a>.</td><td></td><td></td></tr><tr><td>MV-014-212<br/><em>Viral vector</em><br/><em>(RSV)</em><br/><br/><em>Meissa Vaccines (USA)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/MV-014-212%20Meissa%20Vaccines/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Intranasal drops or spray. </td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04798001" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/><strong><a href="https://www.businesswire.com/news/home/20211028005281/en/Meissa-Announces-Positive-Preliminary-Clinical-Data-on-Safety-and-Immunogenicity-of-Intranasal-COVID-19-Vaccine" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong> (press release).</td><td></td><td></td></tr><tr><td>MVA-SARS-2ST<br/><em>Viral vector (MVA)</em><br/><br/><em>German Centre for Infection Research (DZIF)/IDT Biologika</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/MVA-SARS-2S%20German%20Centre%20for%20Infection%20Research%20(DZIF)%2FIDT%20Biologika/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Inhalation.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT05226390" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.</td><td></td><td></td></tr><tr><td>*NDV-HXP-S<br/><em>Viral vector (Newcastle Disease Virus)</em><br/><br/><em>Castlevax/Icahn Mt Sinai</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/NDV-HXP-S%20-%20Icahn%20School%20of%20Medicine%20Mt%20Sinai/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)<br/></td><td>Intranasal.</td><td><a href="https://www.clinicaltrials.gov/study/NCT05181709" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/><strong><a href="https://www.mountsinai.org/about/newsroom/2023/promising-results-of-next-generation-intranasal-covid-booster-vaccine-implications-for-infection-prevention-and-transmission" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong> (press release).</td><td></td><td></td></tr><tr><td>Patria (NDV-HXP-S/AVX-COVID-12-HEXAPRO)<br/><em>Viral vector (Newcastle Disease Virus)</em><br/><br/><em>Laboratorio Avi-Mex (Mexico)</em><br/>(All records on <a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/NDV-HXP-S%2FPatria%20(AVX-COVID-12-HEXAPRO)%20Avimex/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Patria</a>, see NDV-HXP-S above for early development.)<br/><br/></td><td>Intranasal.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04871737" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/><strong><a href="https://www.nature.com/articles/s41541-023-00662-6" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong>.<br/><br/><a href="https://clinicaltrials.gov/ct2/show/NCT05205746" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 2</a>.<br/><strong><a href="https://avimex.com.mx/noticias-y-eventos/45" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong> (press release).</td><td></td><td><br/></td></tr><tr><td>PRAK-03202<br/><em>Protein subunit</em><br/><br/><em>Oravax (USA) [Oravax was established by OraMed (Israel) to develop this vaccine, using Premas Biotech’s PRAK-03202 and their oral vaccine technology]</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/PRAK-03202%20Oravax%2FOramed/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a> on oral PRAK-03202, and <a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/PRAK%E2%88%9203202%20Premas%20Biotech/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">on intramuscular version</a>)</td><td>Oral.</td><td><a href="https://sanctr.samrc.ac.za/TrialDisplay.aspx?TrialID=5673" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a> (in South Africa).<br/><strong><a href="https://www.prnewswire.com/news-releases/oramed-subsidiary-oravax-reports-positive-preliminary-phase-1-data-for-its-oral-covid-19-vaccine-301643522.html" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results </a></strong>(press release only).</td><td></td><td></td></tr><tr><td>Razi Cov Pars<br/><em>Protein subunit</em><br/><br/><em>Razi Vaccine &amp; Serum Research Institute (Iran)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/Razi%20Cov%20Pars%20-%20Razi%20Vaccine%20%26%20Serum%20Research%20Institute/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Intranasal (third dose after 2 injections).</td><td><a href="https://www.irct.ir/trial/52975" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/><strong><a href="https://www.mdpi.com/2076-393X/11/2/455" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong>.<br/><br/><a href="https://www.irct.ir/trial/55238" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 2</a>.<br/><br/><a href="https://www.irct.ir/trial/61378" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1 to 2</a> (in 12-17 year-olds).</td><td>41,128 people in Iran, comparing the 3-dose course to 2-dose inactivated Sinopharm Beijing vax (<a href="https://www.irct.ir/trial/58143" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 3</a>). (Press report of <strong><a href="https://www.farsnews.ir/en/news/14001123000446/Razi-Insie-Chief-Underlines-High-Efficiency-f-Iran-Made-Razi-Cv-Pars" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">results</a></strong>, in the <a href="https://www.tasnimnews.com/fa/news/1400/11/20/2659676/%D8%A7%D8%AB%D8%B1%D8%A8%D8%AE%D8%B4%DB%8C-%D9%88%D8%A7%DA%A9%D8%B3%D9%86-%D8%B1%D8%A7%D8%B2%DB%8C-3-%D8%A8%D8%B1%D8%A7%D8%A8%D8%B1-%D8%B3%DB%8C%D9%86%D9%88%D9%81%D8%A7%D8%B1%D9%85-%D8%A7%D8%B3%D8%AA-%D8%A7%D9%85%DA%A9%D8%A7%D9%86-%D8%A7%D8%B3%D8%AA%D9%81%D8%A7%D8%AF%D9%87-%D8%A7%D8%B2-%D8%AF%D9%88%D8%B2-%D8%A7%D8%B3%D8%AA%D9%86%D8%B4%D8%A7%D9%82%DB%8C-%D8%A8%D9%87-%D8%B9%D9%86%D9%88%D8%A7%D9%86-%D8%AF%D9%88%D8%B2-%D8%B3%D9%88%D9%85-%D9%88%D8%A7%DA%A9%D8%B3%D9%86-%D9%87%D8%A7%DB%8C-%DA%A9%D8%B1%D9%88%D9%86%D8%A7" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">first 24,000</a> participants.)</td><td>There were no hospitalizations for Covid in the Razi Cov Pars group and 5 in the Sinopharm group. The rate of Covid was reportedly more than twice as high in the Sinopharm group.</td></tr><tr><td>SC-Ad6-1<br/><em>Viral vector (adenovirus)</em><br/><br/><em>Moat Bio/Tetherex (USA)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/SC-Ad6-1%20Mayo%20Clinic%2FTetherex%20Pharmaceuticals" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Intranasal and inhaled.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04839042" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/>Trial expanded to add an inhaled version (from 130 to 190 people). Results so far briefly mentioned in <a href="https://www.prnewswire.com/news-releases/moat-biotechnology-raises-6-5m-in-first-close-for-intranasalinhaled-covid-19-vaccine-301849665.html" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">press release</a>.</td><td></td><td></td></tr><tr><td>(Unnamed)<br/><em>Inactivated bacteria</em><br/><br/><em>DreamTec (Hong Kong)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/Unnamed%20-%20DreamTec/search/dreamtec/titleCreatorYear/item-list" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Oral.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT05057923" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/><a href="https://clinicaltrials.gov/ct2/show/NCT05158855" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/><a href="https://clinicaltrials.gov/ct2/show/NCT05239923" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/><br/><em>Note: </em>An article of <a href="https://www.mdpi.com/2076-393X/10/11/1852" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">preclinical results has been retracted</a> over lack of ethics committee approval. </td><td></td><td></td></tr><tr><td>VXA-CoV2-1/VXA-CoV2-1.1-S<br/><em>Viral vector</em><br/><em>(adenovirus)</em><br/><br/><em>Vaxart (USA)</em><br/>(<a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/tags/VXA-CoV2-1%20-%20Vaxart/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All records</a>)</td><td>Tablets.</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04563702" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1</a>.<br/><strong><a href="https://www.medrxiv.org/content/10.1101/2022.07.16.22277601v1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong>.<br/><br/><a href="https://clinicaltrials.gov/ct2/show/NCT05067933" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 2</a>. (Recruiting: started October 1, 2021.)<br/><strong><a href="https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-positive-top-line-phase-ii-clinical-study-data" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Results</a></strong> (press release).</td><td>Omicron adaptation was developed for an Omicron challenge trial, originally <a href="https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-positive-top-line-phase-ii-clinical-study-data" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">planned</a> for second half of 2023.<br/><br/>This vax is<a href="https://www.proactiveinvestors.co.uk/companies/news/1009235/hvivo-manufactures-omicron-human-challenge-study-1009235.html" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer"> now on hold</a>, as Vaxart is trying to develop an oral pan-betacoronavirus vaccine.</td><td><br/></td></tr></tbody></table></figure>







<p><em><a href="#contents">Back to contents</a></em></p>



<h2 id="pantable"></h2>







<h4>Addendum 2: <strong><em>Pancoronavirus vaccines with preclinical results</em></strong></h4>







<p>* <em>Indicates new entry since previous update post. </em>  </p>







<figure><table><thead><tr><th>Developer<br/><em>Country</em><br/><br/><em>Vaccine name</em></th><th>Type of:<br/><br/>Vaccine<br/><br/><em>Coronavirus</em></th><th>Preclinical results</th><th>Clinical trial status</th></tr></thead><tbody><tr><td>California Institute of Technology (Caltech)<br/><em>USA</em><br/><br/><em>Mosaic-8b</em></td><td>Protein subunit<br/><br/><em>Beta</em></td><td><a href="https://www.science.org/doi/10.1126/science.abf6840" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a><br/><br/><a href="https://www.biorxiv.org/content/10.1101/2023.02.24.529520v1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a><br/><br/><a href="https://www.sciencedirect.com/science/article/pii/S107476132200560X" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a><br/><br/><a href="https://www.science.org/doi/10.1126/science.abq0839" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Primate, non-primate</a></td><td></td></tr><tr><td>Codiak<br/><em>USA</em><br/><br/><em>exoVACC Pan Beta Coronavirus</em></td><td>Protein subunit<br/><br/><em>Beta</em><br/></td><td><a href="https://www.sciencedirect.com/science/article/pii/S0092867421007972" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Article on development</a><br/><br/>Non-primate (<a href="https://s3.us-east-1.amazonaws.com/codiak-assets.investeddigital.com/publications/Codiak-WVIC-Poster-for-exoVACC-120221-FINAL.pdf" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">conference slides</a>)<br/><br/>Non-primate<br/>(<a href="https://s3.us-east-1.amazonaws.com/codiak-assets.investeddigital.com/publications/Codiak-World-Vaccine-Congress-April-20-2022-Final-V2.pdf" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">conference slides</a>)</td><td><em>(This company <a href="https://cases.stretto.com/codiak" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">began proceedings</a></em><br/><em>in bankruptcy court. See news.)</em></td></tr><tr><td>DIOSynvax<br/><em>UK</em><br/><br/><em>DIOS-CoVax/<br/>pEVAC-PS</em></td><td>mRNA<br/><br/><em>Sarbeco</em></td><td><a href="https://www.researchsquare.com/article/rs-995273/v1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a></td><td><a href="https://www.isrctn.com/ISRCTN87813400" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1 trial</a> (incl. protocol)<br/><em>(Up to 36 participants)</em><br/>Began <a href="https://www.cam.ac.uk/stories/DIOSCoVax_safetytrial" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">December 2021</a>.<br/>Fully recruited.<br/><a href="https://www.nihr.ac.uk/news/trials-launched-for-revolutionary-needle-free-coronavirus-vaccine/33575" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Expanded </a>to another city – no trial register entry found.</td></tr><tr><td>Duke University<br/><em>USA</em><br/><br/><em>RBD–scNP</em></td><td>Protein subunit<br/><br/><em>Beta</em><br/></td><td><a href="https://www.nature.com/articles/s41586-021-03594-0" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Primate</a><br/><br/><a href="https://www.nature.com/articles/s41467-022-33985-4" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Primate, non-primate</a><br/><br/><a href="https://www.biorxiv.org/content/10.1101/2023.05.22.540829v1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a></td><td></td></tr><tr><td>Francis Crick Institute<br/><em>UK</em><br/><br/><em>(Unnamed)</em></td><td>Protein subunit with DNA boost<br/><br/><em>All</em></td><td><a href="https://www.science.org/doi/10.1126/scitranslmed.abn3715" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a></td><td></td></tr><tr><td>Fudan University<br/><em>China</em><br/><br/><em>CF501</em></td><td>Protein subunit<br/><br/><em>Sarbeco</em></td><td><a href="https://www.nature.com/articles/s41422-022-00612-2" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Primate, non-primate</a><br/><br/><a href="https://www.nature.com/articles/s41422-022-00631-z" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Primate</a><br/><br/><a href="https://www.pnas.org/doi/full/10.1073/pnas.2221713120" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Primate</a></td><td></td></tr><tr><td>Inserm Vaccine Research Institute<br/><em>France</em><br/><br/><em>CD40.CoV2</em></td><td>Protein subunit<br/><em>Sarbeco</em></td><td><a href="https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(22)00243-2/fulltext" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a><br/><br/><a href="https://www.nature.com/articles/s41467-021-25382-0" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Primate, non-primate</a><br/><br/><a href="https://elifesciences.org/articles/75427" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Primate</a><br/><br/><a href="https://www.croiconference.org/wp-content/uploads/sites/2/posters/2023/CROI-Poster-Nguema020223-133204312648122137.pdf" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a> <em>(conference poster)</em></td><td></td></tr><tr><td>Oragenics/Inspirevax/ National Research Council of Canada<br/><em>USA, Canada</em><br/><br/><em>NT-CoV2-1</em></td><td>Protein subunit<br/>(Intranasal)<br/><br/><em>All</em></td><td><a href="https://www.nature.com/articles/s41598-021-01363-7" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a> <em>(original vax)</em><br/><br/><a href="https://www.nature.com/articles/s41598-022-13819-5" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a> <em>(original vax)</em></td><td></td></tr><tr><td>* Osivax<br/><em>France</em><br/><br/>OVX033</td><td>Protein subunit<br/><br/><em>Sarbeco</em></td><td><a href="https://www.frontiersin.org/articles/10.3389/fimmu.2023.1188605/full" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a></td><td></td></tr><tr><td>Pennsylvania State University<br/><em>USA</em><br/><br/><em>(Unnamed)</em></td><td>Protein subunit<br/><br/><em>All</em></td><td><a href="https://onlinelibrary.wiley.com/doi/10.1002/adfm.202206055" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a></td><td></td></tr><tr><td>Scripps Research Institute<br/><em>USA</em><br/><br/><em>(Unnamed)</em></td><td>Protein subunit<br/><br/><em>Beta</em></td><td><br/><br/><a href="https://www.science.org/doi/10.1126/sciadv.abj3107" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a></td><td></td></tr><tr><td>SK Bioscience/ Uni of Washington/Uni of North Carolina at Chapel Hill<br/><em>South Korea, USA</em><br/><br/><em>GBP511</em></td><td>Protein subunit<br/><br/><em>Sarbeco</em></td><td><a href="https://www.science.org/doi/epdf/10.1126/scitranslmed.adg7404" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Primate, non-primate</a> <em>(testing Covid vaccine GBP510 against other sarbecoviruses)</em><br/></td><td><em>(<a href="https://cdn.who.int/media/docs/default-source/blue-print/dev_sk-biosciences_king_whoconsultation_pan-sarbecovirus_28jan2022.pdf?sfvrsn=53bc4a23_7" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">More on plans for adapting this vaccine</a> – GBP510 authorized as SKYCovione.)</em></td></tr><tr><td>* Stanford University<br/><em>USA</em><br/><br/><em>DCFHP-alum</em></td><td>Protein subunit<br/><br/><em>Sarbeco</em></td><td><a href="https://www.nature.com/articles/s41467-023-37417-9" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Primate</a><br/><br/><a href="https://www.biorxiv.org/content/10.1101/2023.06.27.546764v2" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a><br/></td><td></td></tr><tr><td>University of California Irvine<br/><em>USA</em><br/><br/><em>(Unnamed)</em></td><td>Viral vector<br/><br/><em>Beta</em></td><td><a href="https://www.biorxiv.org/content/10.1101/2023.05.24.541850v1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a><br/><br/><a href="https://www.biorxiv.org/content/10.1101/2023.05.23.542024v1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a> (mucosal)<br/><br/><em>(There was also a paper about this vaccine’s development <a href="https://journals.aai.org/jimmunol/article/206/11/2566/234252/Genome-Wide-B-Cell-CD4-and-CD8-T-Cell-Epitopes" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">in 2021</a>.)</em></td><td></td></tr><tr><td>University of North Carolina at Chapel Hill<br/><em>USA</em><br/><br/><em>(Unnamed)</em></td><td>Viral vector<br/><br/><em>Sarbeco</em></td><td><a href="https://www.biorxiv.org/content/10.1101/2022.11.28.518175v1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a></td><td></td></tr><tr><td>University of Toronto<br/><em>Canada</em><br/><br/><em>(Unnamed)</em></td><td>Protein subunit<br/><br/><em>Sarbec</em>o</td><td><a href="https://www.cell.com/cell-reports/fulltext/S2211-1247(23)00402-3" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a></td><td></td></tr><tr><td>University of Wisconsin-Madison (PanCorVac)<br/><em>USA</em><br/><br/><em>(Unnamed)</em></td><td>Protein subunit<br/><br/><em>All</em></td><td><a href="https://www.nature.com/articles/s42003-021-02128-8" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a><br/><br/><a href="https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(22)00523-0/fulltext" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a><br/><br/>* <a href="https://www.researchsquare.com/article/rs-3088907/v1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a><br/><br/></td><td></td></tr><tr><td>VBI Vaccines<br/><em>Canada</em><br/><br/><em>VBI-2901</em></td><td>eVLP<br/><br/><em>All</em></td><td><a href="https://www.biorxiv.org/content/10.1101/2021.09.28.462109v1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a><br/><br/><a href="https://www.vbivaccines.com/press-releases/new-data-and-progress-of-vbi-2900-coronavirus-program/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a> (Press release)<br/></td><td><a href="https://clinicaltrials.gov/ct2/show/NCT05548439" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1 trial</a><br/><em>(103 participants)</em><br/>Began October 2022.<br/>Fully recruited.<br/>(<a href="https://cdn.who.int/media/docs/default-source/blue-print/dev_vbi-vaccines_whoconsultation_pan-sarbecovirus_28jan2022.pdf?sfvrsn=2b17ebb1_12" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Further background info</a>.)</td></tr><tr><td>Walter Reed Army Institute of Research (WRAIR)<br/><em>USA</em><br/><br/><em>SpFN</em> <em>1B-06-PL</em></td><td>Protein subunit<br/><br/><em>Beta</em></td><td><a href="https://www.nature.com/articles/s41541-021-00392-7" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a><br/><br/><a href="https://www.nature.com/articles/s41541-021-00414-4" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a><br/><br/><a href="https://www.cell.com/cell-reports/fulltext/S2211-1247(21)01639-9" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a> (incl RFN)<br/><br/><a href="https://www.nature.com/articles/s41541-023-00638-6" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a><br/><br/><a href="https://www.science.org/doi/10.1126/scitranslmed.abi5735" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Primate</a><br/><br/><a href="https://www.mdpi.com/2076-393X/10/5/717" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Primate</a><br/><br/><a href="https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(23)00128-3" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Primate</a> (with J&amp;J vax)</td><td><a href="https://clinicaltrials.gov/ct2/show/NCT04784767" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Phase 1 trial</a><br/><em>(29 participants)</em><br/>Began April 2021.<br/>Results <a href="https://www.defenseone.com/technology/2021/12/us-army-creates-single-vaccine-effective-against-all-covid-sars-variants/360089/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">described</a> as “positive” – no data reported yet.<br/><a href="https://cdn.who.int/media/docs/default-source/blue-print/9.-modjarrad_vaccine-strategies_r-d-who-consultation_march-25-2020.pdf?sfvrsn=b7d46cdf_7" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Additional detail</a> on phase 1 trial.</td></tr><tr><td>Walter Reed Army Institute of Research (WRAIR)<br/><em>USA</em><br/><br/><em>RFN</em></td><td>Protein subunit<br/><br/><em>Beta</em></td><td><a href="https://www.cell.com/cell-reports/fulltext/S2211-1247(21)01639-9" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a> (incl SpFN)<br/><br/><a href="https://www.pnas.org/doi/10.1073/pnas.2106433118" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Primate</a></td><td></td></tr><tr><td>Yale University<br/><em>USA</em><br/><br/><em>(Unnamed)</em></td><td>mRNA<br/><br/><em>All</em></td><td><a href="https://www.nature.com/articles/s41467-022-30878-4" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a><br/><br/><a href="https://www.biorxiv.org/content/10.1101/2022.05.07.491038v1" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a></td><td></td></tr><tr><td>Yale University/Xanadu Bio<br/><em>USA</em><br/><br/><em>(Unnamed)</em></td><td>Protein subunit, intranasal booster<br/><br/><em>Sarbeco</em></td><td><a href="https://www.science.org/doi/10.1126/science.abo2523" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Non-primate</a></td><td></td></tr></tbody></table></figure>







<p><em><a href="#contents">Back to contents</a></em></p>







<h2 id="definitions"></h2>







<h4><em>Addendum 3:</em> Definitions of vaccine types</h4>







<ul><li>Mucosal vaccines: These enter the body the way the virus does – through mucosal tissues. It’s hoped that provides defence against infection. They can be administered via different routes – squirts or drops in the nose, inhaled through the mouth through a nebulizer (similar to an asthma medication), or in tablet, capsule, or sublingual form.</li><li>Pan-SARS-CoV-2 or “variant-proof” vaccines: These aim to provide protection against any variant of the coronavirus that causes Covid-19 – including future variants.</li><li>Pancoronavirus can be targeted to:<ul><li>the “subgroup” the 2 SARS viruses came from (the sarbecovirus subgenus),</li><li>coronaviruses from the next level up (the genus, betacoronavirus, which includes lethal diseases like MERS, as well as common cold viruses), or</li><li>the whole coronavirus family – it has 4 genuses, including betacoronavirus and alphacoronavirus (with more common cold viruses).</li></ul></li></ul>



<p>I classify a vaccine as a pancoronavirus one when the developers are explicitly targeting coronaviruses more broadly than SARS-CoV-2, and have tested for signs of response to non-SARS-CoV-2 coronavirus(es) (or clearly plan to).</p>







<p><em><a href="#contents">Back to contents</a></em></p>







<p><em>You can keep up with my work at my newsletter, <a href="https://hildabastian.wordpress.com/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Living With Evidence</a>. And I’m active on Mastodon: <a href="https://mastodon.online/@hildabast" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">@hildabast@mastodon.online</a> </em></p>







<p>~~~~</p>







<p><em>For details on how I track Covid vaccine progress, see my <a href="https://absolutelymaybe.plos.org/2023/05/01/a-process-update-on-covid-vaccine-tracking/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">background post</a>.</em> <em>Notes</em> <em>on my collection of studies are <a href="https://absolutelymaybe.plos.org/2022/01/26/boosters-and-mixed-schedules-covid-vaccines-at-the-2-year-mark-part-1/#collection" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">here</a>. The collection is in a public Zotero library you can dig into <a href="https://www.zotero.org/groups/2528572/covid-19_vaccine_results/library" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">here</a>.</em></p>



<p><strong><em>Previous update posts on next generation Covid vaccines:</em></strong></p>



<ol><li>Mucosal vaccines (<a href="https://absolutelymaybe.plos.org/2022/03/30/the-race-to-reduce-covid-19-transmission-an-update-on-66-intranasal-6-oral-vaccines/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">March 2022</a>)</li><li>Pan-SARS-Cov-2 and pancoronavirus (<a href="https://absolutelymaybe.plos.org/2022/07/09/front-runners-in-the-race-for-variant-proof-and-all-coronavirus-vaccines/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">July 2022</a>)</li><li>Mucosal vaccines (<a href="https://absolutelymaybe.plos.org/2022/07/31/next-generation-covid-vaccine-update-intranasal-other-mucosal-vaxes/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">July 2022</a>)</li><li>Mucosal vaccines (<a href="https://absolutelymaybe.plos.org/2022/09/29/intranasal-co-a-very-big-month-for-mucosal-covid-vaccines/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">September 2022</a>)</li><li>Mucosal vaccines (<a href="https://absolutelymaybe.plos.org/2023/04/21/progress-on-intranasal-oral-covid-vaccines-plus-a-us-government-funding-boost/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">April 2023</a>)</li><li>Pancoronavirus vaccines (<a href="https://absolutelymaybe.plos.org/2023/04/26/pancoronavirus-vaccines-update-lots-of-preclinical-results-another-trial-underway/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">April 2023</a>)</li></ol>



<p><strong><em><a href="https://absolutelymaybe.plos.org/?post_tag=covid-19-vaccine-race" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer"><br/></a></em></strong><em><a href="https://absolutelymaybe.plos.org/?post_tag=covid-19-vaccine-race" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All my Absolutely Maybe Covid-19 vaccine posts</a></em></p>



<p><em><a href="https://absolutelymaybe.plos.org/?category=covid-19" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">All previous Covid-19 posts at Absolutely Maybe</a></em></p>



<p><em>My posts</em> <em><a href="https://www.theatlantic.com/author/hilda-bastian/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">at The Atlantic</a>, </em><a href="https://www.wired.com/author/hilda-bastian/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer"><em>at WIRED</em></a><em>, and debunking posts <a href="http://hildabastian.net/index.php/covid-19" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">at my personal website</a>.</em></p>



<p><em>Disclosures: My interest in Covid-19 vaccine trials is as a person worried about the virus, as my son is immunocompromised: I have no financial or professional interest in the vaccines. I have worked for an institute of the NIH in the past, but not the one working on vaccines (<a href="https://www.niaid.nih.gov/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">NIAID</a>). <a href="https://blogs.plos.org/absolutely-maybe/about-hilda-bastian/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">More about me</a>.</em></p>



<p><em>The cartoons are my own <a href="http://creativecommons.org/licenses/by-nc-nd/4.0/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">(CC BY-NC-ND license)</a></em>. <em>(More cartoons at <a href="http://statistically-funny.blogspot.com/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Statistically Funny</a>.)</em></p>







<p></p>

<p>The post <a href="https://absolutelymaybe.plos.org/2023/07/31/next-generation-covid-vaccines-update-no-9-major-new-hat-in-the-ring-plus-important-results/" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Next Generation Covid Vaccines Update (No 9): Major New Hat in the Ring Plus Important Results</a> appeared first on <a href="https://absolutelymaybe.plos.org" rel="noopener noreferrer" target="_blank" referrerpolicy="no-referrer">Absolutely Maybe</a>.</p>
